Evidence map›Paper›PMID 26366945›Full record

ReviewEpigenomics2015

Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis.

Zhifu Sun, Julie Cunningham, Susan Slager, Jean-Pierre Kocher

Abstract readReview
In one paragraph

Review in Epigenomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. A Clinician's Guide to Bioinformatics for Next-Generation Sequencing.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhifu SunDivision of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN 55905, USA.
Julie CunninghamMedical Genome Facility, Mayo Clinic, Rochester, MN 55905, USA.
Susan SlagerDivision of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN 55905, USA.
Jean-Pierre KocherDivision of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN 55905, USA.

Funding

Genetic Epidemiology of Chronic Lymphocytic LeukemiaU01CA118444 · NCI · MAYO CLINIC ROCHESTER · PI SLAGER, SUSAN L · 2006 to 2015
$7.1M
NCI NIH HHS R01CA118444NCI NIH HHS U01 CA118444
6 · The paper itself

Abstract

Bisulfite treatment-based methylation microarray (mainly Illumina 450K Infinium array) and next-generation sequencing (reduced representation bisulfite sequencing, Agilent SureSelect Human Methyl-Seq, NimbleGen SeqCap Epi CpGiant or whole-genome bisulfite sequencing) are commonly used for base resolution DNA methylome research. Although multiple tools and methods have been developed and used for the data preprocessing and analysis, confusions remains for these platforms including how and whether the 450k array should be normalized; which platform should be used to better fit researchers' needs; and which statistical models would be more appropriate for differential methylation analysis. This review presents the commonly used platforms and compares the pros and cons of each in methylome profiling. We then discuss approaches to study design, data normalization, bias correction and model selection for differentially methylated individual CpGs and regions.

Indexed as

DNA MethylationAlgorithmsCpG IslandsDNAEpigenomicsGenome, HumanHigh-Throughput Nucleotide SequencingHumansModels, GeneticSulfitesDNAhydrogen sulfiteSulfitesbisulfite sequencingdifferential methylationDNA methylationmethylation 450K arraynormalizationreduced representation bisulfite sequencingstudy design

Identifiers

PMID26366945
PMCPMC4790440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.